Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02471651 · ClinicalTrials.gov registry record · Phase 4

Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema

A Phase 4 study, sponsored by California Retina Consultants.

Completed
Registry status
Phase 4
Development phase
40
Enrollment target

NCT02471651 is a Phase 4 study that has completed, run by California Retina Consultants. The registered enrollment target is 40 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02471651, a Phase 4 study, has completed, sponsored by California Retina Consultants.

COMPLETED
Registry status
Phase 4
Development phase
40 participants
Enrollment target

Study Summary

Laser photocoagulation and intravitreal anti-vascular growth factor injections are commonly used treatment options for individuals with diabetic macular edema. However, some patients continue to experience persistent diabetic macular edema and poor vision despite continued laser and/or anti-vegf therapy. Recent clinical trials suggest that due to inflammatory mediators dexamethasone intravitreal implant (0.7mg) may be a good alternative therapy for individuals unresponsive to laser photocoagulation or intravitreal anti-vascular growth factor injections. The purpose of this research study is to compare the effectiveness of using a dexamethasone steroid implant versus monthly intravitreal anti-VEGF injections for research participants with persistent diabetic macular edema (DME).

Interventions

  • DRUG Dexamethasone intravitreal implant (0.7 mg)
  • DRUG Intravitreal anti-VEGF injection

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2015-06
Est. Completion 2018-10-24
Phase Phase 4

Sponsor

California Retina Consultants

8 total trials

What the Registry Record Tells You About NCT02471651

The ClinicalTrials.gov registry entry for NCT02471651 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is California Retina Consultants, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Dexamethasone intravitreal implant (0.7 mg) is the first listed.

NCT02471651 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02471651 about?

NCT02471651 is a clinical study titled "Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema". Laser photocoagulation and intravitreal anti-vascular growth factor injections are commonly used treatment options for individuals with diabetic macular edema. However, some patients continue to experience persistent diabetic macular edema and poor vision despite continued laser and/or anti-vegf the...

What is the current status of trial NCT02471651?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2015-06. Estimated completion is 2018-10-24.

What interventions are being tested in trial NCT02471651?

The interventions under investigation include: Dexamethasone intravitreal implant (0.7 mg) (DRUG), Intravitreal anti-VEGF injection (DRUG).

Who is sponsoring clinical trial NCT02471651?

This trial is sponsored by California Retina Consultants, which has 8 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.